Potential clinical applications of our findings include preliminary support for plasma NfL as a potential biomarker associated with episodic memory regardless of the status of more recently established Alzheimer’s disease biomarkers, such as those within the AT(N) framework. The gene discussed is NEFL; the disease is early-onset autosomal dominant Alzheimer disease.